Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.53 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.52 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191619 | 0.86 | XDH (0.54) | XDHSLC22A12PIP4K2APIP4K2BGSK3B | |
| SCHEMBL4187483 | 0.83 | ALPL (0.49) | XDHSLC22A12PIP4K2APIP4K2BPTGS2 | |
| SCHEMBL4192415 | 0.81 | XDH (0.59) | XDHSLC22A12PIP4K2APIP4K2BPTGS2 | |
| SCHEMBL4196597 | 0.79 | CYP1A2 (0.60) | XDHSLC22A12PIP4K2APIP4K2BPTGS2 | |
| SCHEMBL4183083 | 0.78 | TDP2 (0.59) | XDHSLC22A12PIP4K2APIP4K2BPTGS2 | |
| SCHEMBL3245767 | 0.78 | MEN1 (0.58) | GSK3BPTGS2KDM1A | |
| SCHEMBL21915556 | 0.78 | FDPS (0.56) | XDHSLC22A12PIP4K2APIP4K2BPIK3CB | |
| SCHEMBL4187260 | 0.77 | XDH (0.63) | XDHSLC22A12PIP4K2APIP4K2B | |
| SCHEMBL5700416 | 0.75 | PIK3CG (0.50) | PTGS2PIK3CGPIK3CB | |
| SCHEMBL4199106 | 0.73 | JAK2 (0.53) | PTGS2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1644365-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | Biofocus Discovery Ltd (GB) | 2006-04-12 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005003101-A2 | PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | XDH 750/4885SLC22A12 4511/4885PIP4K2A 589/4885 |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885PIP4K2A 748/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885PIP4K2A 748/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | XDH 1630/4885SLC22A12 3973/4885PIP4K2A 748/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | XDH 527/4885SLC22A12 2928/4885PIP4K2A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.